NCT06747845 - Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

January 30, 2029

Conditions

Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG

Niraparib

Niraparib 200mg PO daily on days 1-21 of each 21-day cycle.

DRUG

FOLFIRI

Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.

DRUG

Ipilimumab

Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.

Trial Locations (2)

RECRUITING

University of Pennsylvania, Abramson Cancer Center, Philadelphia

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston